MX367461B - Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa. - Google Patents

Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa.

Info

Publication number
MX367461B
MX367461B MX2015009924A MX2015009924A MX367461B MX 367461 B MX367461 B MX 367461B MX 2015009924 A MX2015009924 A MX 2015009924A MX 2015009924 A MX2015009924 A MX 2015009924A MX 367461 B MX367461 B MX 367461B
Authority
MX
Mexico
Prior art keywords
carboximethylcellulose
sodium hyaluronate
including sodium
artificial tears
tears including
Prior art date
Application number
MX2015009924A
Other languages
English (en)
Other versions
MX2015009924A (es
Inventor
G Vehige Joseph
A Simmons Peter
M Blanda Wendy
A Marsh David
J Beard Bereth
Haixia Liu
S Matsumoto Steven
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2015009924A publication Critical patent/MX2015009924A/es
Publication of MX367461B publication Critical patent/MX367461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se refiere a formulaciones y métodos de uso para formulaciones de gotas oftálmicas que comprenden carboximetilcelulosa (CMC) y ácido hialurónico (HA) con una mejora de la distribución sobre la córnea durante el parpadeo.
MX2015009924A 2013-02-01 2014-02-03 Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa. MX367461B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759710P 2013-02-01 2013-02-01
US201361785857P 2013-03-14 2013-03-14
PCT/US2014/014505 WO2014121232A1 (en) 2013-02-01 2014-02-03 Artificial tears comprising sodium hyaluronate and carboxymethylcellulose

Publications (2)

Publication Number Publication Date
MX2015009924A MX2015009924A (es) 2015-09-25
MX367461B true MX367461B (es) 2019-08-21

Family

ID=50113045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009924A MX367461B (es) 2013-02-01 2014-02-03 Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa.

Country Status (23)

Country Link
US (5) US20140221309A1 (es)
EP (2) EP2950783B1 (es)
JP (2) JP6527468B2 (es)
KR (1) KR102227202B1 (es)
CN (2) CN104981234A (es)
AU (2) AU2014212025A1 (es)
BR (1) BR112015018414B1 (es)
CA (1) CA2898217C (es)
CY (1) CY1124054T1 (es)
DK (2) DK2950783T3 (es)
ES (2) ES2841434T3 (es)
HR (1) HRP20191382T1 (es)
HU (2) HUE044555T2 (es)
LT (1) LT2950783T (es)
MX (1) MX367461B (es)
PL (2) PL2950783T3 (es)
PT (2) PT2950783T (es)
RS (1) RS59271B1 (es)
RU (1) RU2687275C2 (es)
SA (1) SA517381008B1 (es)
SI (2) SI2950783T1 (es)
WO (1) WO2014121232A1 (es)
ZA (1) ZA201505026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3613423T (pt) 2013-07-10 2022-12-07 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170014339A1 (en) * 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
US20180338911A1 (en) * 2015-10-28 2018-11-29 David B. Welch Eye Drops
ES2621877B1 (es) * 2016-01-04 2018-05-04 Agencia Pública Empresarial Sanitaria Hospital De Poniente Solución para resección endoscópica
US10632202B2 (en) * 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
RS67599B1 (sr) * 2017-06-09 2026-01-30 Omnivision Gmbh Kompozicija za lečenje suvog oka
US12303527B2 (en) * 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
EP3852725A4 (en) * 2018-09-20 2022-08-03 The Hong Kong University of Science and Technology EYE DROP COMPOSITIONS
KR102051356B1 (ko) * 2019-01-03 2019-12-03 (주)휴온스 고농도의 히알루론산 또는 그의 염을 함유하는 점안 조성물
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
MX2023010372A (es) 2021-03-10 2023-09-12 Bausch & Lomb Ireland Ltd Soluciones oftálmicas.
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
CA2371833C (en) * 1999-02-19 2009-09-15 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid gel composition, process for its production and medical material containing it
CA2365767A1 (en) 1999-03-15 2000-09-21 Trustees Of Boston University Angiogenesis inhibition
BR0015436A (pt) * 1999-11-09 2002-07-16 Alcon Inc Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
ATE283715T1 (de) * 1999-12-17 2004-12-15 Genzyme Corp Chirurgische prothese
CN1485395A (zh) * 2002-09-25 2004-03-31 宋海涛 一种环保型“冷热液”
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
JP2006052160A (ja) * 2004-08-10 2006-02-23 Rohto Pharmaceut Co Ltd ドライアイ治療用眼科組成物
JP2006143590A (ja) * 2004-10-21 2006-06-08 Rohto Pharmaceut Co Ltd 粘膜適用組成物
CN101056614A (zh) * 2004-11-09 2007-10-17 眼力健有限公司 眼用溶液
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
WO2008011836A2 (es) * 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
CA2914805C (en) * 2006-11-06 2017-12-12 Alcon Inc. Ocular devices and methods of making and using thereof
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
KR100827400B1 (ko) * 2008-06-24 2008-05-06 김정춘 파이프 연결구를 갖는 수도계량기 및 그 제조방법
KR100938500B1 (ko) * 2008-06-24 2010-01-28 주식회사 디에이치피코리아 안과질환 예방 및 치료용 점안제 조성물
US20100086512A1 (en) 2008-10-02 2010-04-08 Rolf Schaefer Mucomimetic compositions and uses therefore
EP2349232A1 (en) * 2008-10-20 2011-08-03 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
TWI620569B (zh) * 2009-12-15 2018-04-11 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
CN101785852A (zh) * 2010-01-21 2010-07-28 孙杰 一种真皮层微量介入美容抗衰除皱制剂与方法
CN101884602A (zh) * 2010-03-03 2010-11-17 孙杰 一种皮肤美容修复抗衰除皱的化妆品制剂

Also Published As

Publication number Publication date
MX2015009924A (es) 2015-09-25
RS59271B1 (sr) 2019-10-31
JP6527468B2 (ja) 2019-06-05
US20240285673A1 (en) 2024-08-29
ES2741141T3 (es) 2020-02-10
BR112015018414A2 (pt) 2017-07-18
DK2950783T3 (da) 2019-07-22
WO2014121232A1 (en) 2014-08-07
RU2687275C2 (ru) 2019-05-13
BR112015018414B1 (pt) 2022-11-08
HUE052793T2 (hu) 2021-05-28
HK1218517A1 (en) 2017-02-24
EP2950783A1 (en) 2015-12-09
HRP20191382T1 (hr) 2019-11-15
SI2950783T1 (sl) 2019-10-30
CA2898217C (en) 2021-08-31
US20160235780A1 (en) 2016-08-18
CA2898217A1 (en) 2014-08-07
KR20150113156A (ko) 2015-10-07
SI3517100T1 (sl) 2021-02-26
PT3517100T (pt) 2020-12-15
LT2950783T (lt) 2019-10-25
KR102227202B1 (ko) 2021-03-12
RU2015132974A (ru) 2017-03-06
ZA201505026B (en) 2016-07-27
PL2950783T3 (pl) 2019-11-29
US20140221309A1 (en) 2014-08-07
CY1124054T1 (el) 2022-03-24
EP2950783B1 (en) 2019-05-15
HUE044555T2 (hu) 2019-11-28
CN104981234A (zh) 2015-10-14
US20220096531A1 (en) 2022-03-31
JP6876079B2 (ja) 2021-05-26
JP2016507529A (ja) 2016-03-10
SA517381008B1 (ar) 2019-08-31
JP2019112411A (ja) 2019-07-11
EP3517100A1 (en) 2019-07-31
AU2018260857B2 (en) 2020-05-07
PL3517100T3 (pl) 2021-04-19
AU2014212025A1 (en) 2015-08-20
DK3517100T3 (da) 2020-12-14
ES2841434T3 (es) 2021-07-08
US20260069627A1 (en) 2026-03-12
EP3517100B1 (en) 2020-09-09
CN111419794A (zh) 2020-07-17
PT2950783T (pt) 2019-08-21
AU2018260857A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CY1124054T1 (el) Τεχνητα δακρυα που περιεχουν υαλουρονικο νατριο και καρβοξυμεθυλοκυτταρινη
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
BR112017011327A2 (pt) sistema e método de detecção de umidificação e sistema de gerenciamento de incontinência
BR112014027582A2 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
PH12017500922A1 (en) Stabilized omega-3 ophthalmic compositions
EP2911671A4 (en) PYRAZOLOPYRIDAZINE AND METHOD FOR THE TREATMENT OF DEGENERATIVE NETWORK DISEASE AND HEARING LOSS WITH USHER SYNDROME
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
BR112015028325A2 (pt) processo para fabricar lítio carboximetil celulose
AR083962A1 (es) Un producto a base de te
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo
BR112014020424A2 (pt) ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata
CO7141425A2 (es) Composiciones oftálmicas con retención y protección de desecación mejoradas
TWD159196S (zh) 眼內鏡片植入具
TWD159197S (zh) 眼內鏡片植入具
CL2010000695A1 (es) Composicion oftalmica acuosa que comprende una ciclosporina,glicerina y agua, donde la composicion contiene menos de 0,3% de cloruro de sodio y menos de 0,04% de metabisulfito de sodio; y uso para tratar una condicion ocular.
TWD176447S (zh) 護目鏡
PL412941A1 (pl) Preparat na zmarszczki
UA36913U (uk) Очна мазь для лікування запальних та дистрофічних захворювань переднього відтинку ока
BR112016002349A2 (pt) composição de vacina substancialmente estável, processo para fabricar uma composição de vacina substancialmente estável, métodos para tratar um paciente e para induzir uma resposta imunogênica, uso de monocloridrato de arginina, e, recipiente

Legal Events

Date Code Title Description
FG Grant or registration